Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.
Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.
3 Motley Fool contributors share their top picks for February.
Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.
The NFL is unquestionably one of the most successful American businesses of all-time. Surprisingly, though, the NFL's 2013 revenues were no match for this single legal drug.
AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?
AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.
Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.
In phase 3 trials, Alkermes' ALKS-5461 shows promise for the treatment of depression.
In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.